Abstract:Alzheimer's disease (AD) is the most common neurodegenerative disorders now. Amyloid ß-protein (Aß) has been recognized as the leading cause of AD, and Aß oligomer plays an important role in the early stage of AD. Anti-Ab immunotherapy targeting on the Ab peptide has been demonstrated as one promising AD treatment. The active immunization, exploiting Ab42 as an immunogen, was initiated on AD animal model by Schenk in 1999 and then advanced to clinical trials. However, the clinical trial was haunted due to an occurrence of subacute meningoencephalitis in 6% of patients. Th1-biased responses stimulated by T cell epitope in the Ab42 and Th1-promoting adjuvant (QS-21) were ascribed to this side effect. Meanwhile, anti-Ab antibodies produced in those patients have been proved to be effective in slowering rate of cognitive decline. As an alternative, passive immunization approaches have the advantage of safety and efficacy over active immunization approaches. In this report, several strains of monoclonal antibody (MAb) against Aß1-42 oligomer or different truncation of Aß C terminal was established for AD therapeutic research. MAb specific for Aß1-42 oligomer was prepared with the hybridoma technique and purified through protein A affinity chromatography. The specificity, affinity and titers of the MAb were analyzed by ELISA, western blot and immunohistochemistry (IHC). To determine whether Antibodies treatment improves the ability of learning and memory, 8-month-old SAMP8 mice and 6-month-old APPswe/PS1DE9 mice were administered intraperitoneally and weekly with 400 mg A8 or nonspecific mouse IgG (Sigma-Aldrich) for 8 weeks. The Morris water maze (MWM) has been used for studying therapy-related changes in learning and memory in mice. The visible, hidden versions of MWM and prob trial were performed. The latency and distance to find the location that had contained the platform was measured. Data were recorded through an overhead camera linked with the computer to quantification of latency and distance. Mice were tested in a blinded manner, with group balanced for genotype and treatment. Mice were sacrificed 3 days after the final MWM manipulation for biochemical and histological assessment. Through western blot (WB) and immunohistochemistry (IHC), the soluble and insoluble Aß, phosphorylation of tau at 181/231/404 site, mTOR (mammalian target of rapamycin), LC3-I/II (microtubuler associated protein 1 light chain 3, MAP1rLC3, LC3), glial fibrillary acidic protein (GFAP), tubulin and actin were detected. Our results showed that the mice serum titer reached over 1:256,000 after immunization. Two hybridoma cell lines (BJ08 and BJNa) secreting MAb specific for the Aß1-42 oligomer was established after sub-cloning. They displayed much higher affinity to low molecular Aß1-42 oligomer, and showed the ability to bind Aß1-42 oligomer in the brain section of SAMP8 mice and APPswe/PS1DE9 mice. Using them as immunotherapy, we show that learning and memory ability was improved through intraperitoneal administration in SAMP8 mice. The mice that found the platform increased in antibody treated groups and our data showed a significant decrease in latency and distance compared with other groups (P < 0.05) (nonspecific mouse IgG, antibody solution buffer and no-treated SAMP8 or APPswe/PS1DE9 mice). Meanwhile, soluble Aß, phosphorylation of tau and LC3-II has also been inhibited after immunotherapy. In addition, the expression level of mTOR, GFAP, tubulin and actin were also detected with IHC and displayed no differences among these groups. In conclusion, the MAbs specific for Aß1-42 oligomer is developed. Therapeutic monoclonal antibodies against Aß oligomers have the efficacy in reducing soluble Aß, phosphorylation of tau and LC3-II level and ultimately ameliorated the learning and memory ability, which paves the way for further diagnostic and therapeutic research on AD.

Effect of Different Aβ Aggregates As Antigen on the Measure of Naturally Occurring Autoantibodies Against Amyloid-β40/42 in IVIG

Naturally Occurring Autoantibodies Against A Beta Oligomers Exhibited More Beneficial Effects In The Treatment Of Mouse Model Of Alzheimer'S Disease Than Intravenous Immunoglobulin

Neuroprotective Effects of IVIG against Alzheimer' s Disease via Regulation of Antigen Processing and Presentation by MHC Class I Molecules in 3xTg-AD Mice

An Enzyme-Linked Immunosorbent Assay To Compare The Affinity Of Chemical Compounds For Beta-Amyloid Peptide As A Monomer

An enzyme-linked immunosorbent assay to compare the affinity of chemical compounds for β-amyloid peptide as a monomer

Effect of anti-Aβ42 antibody on Aβ42 stimulating inflammatory factors production in microglia

[Immunologic Tolerance of Anti-Abeta Antibody in the Sera of AD Patients].

THE STUDY ON SAFETY AND IMMUNIZATION TYPE AFTER INOCULATING WITH DIFFERENT EPITOPE SUBUNIT VACCINE AGAINST β-AMYLOID PEPTIDE

Detection of Amyloid-β(1–42) Aggregation With a Nanostructured Electrochemical Sandwich Immunoassay Biosensor

Changes of Aβ Antibody and Cytokines in Peripheral Blood from Patients with Alzheimer's Disease

How far is the goal of applying β-amyloid in cerebrospinal fluid for clinical diagnosis of Alzheimer's disease with standardization of measurements?

Regenerable and Simultaneous Surface Plasmon Resonance Detection of Aβ(1−40) and Aβ(1−42) Peptides in Cerebrospinal Fluids with Signal Amplification by Streptavidin Conjugated to an N-Terminus-Specific Antibody

Single Chain Fv Antibodies against the 25−35 Aβ Fragment Inhibit Aggregation and Toxicity of Aβ42

Fc N‐glycosylation of autoreactive Aβ antibodies as a blood‐based biomarker for Alzheimer's disease

Competitive Electrochemical Immunoassay For Detection Of Beta-Amyloid (1-42) And Total P-Amyloid Peptides Using Beta-Aminophenol Redox Cycling

An in Vitro Paradigm to Assess Potential Anti-Aβ Antibodies for Alzheimer’s Disease

Therapeutic Monoclonal Antibodies Against Abeta Oligomers for Treatment of Alzheimer's Disease

Detection of plasma Aβ seeding activity by a newly developed analyzer for diagnosis of Alzheimer’s disease

Effects of a Multimerized Recombinant Autoantibody Against Amyloid-β

Intravenous Immunoglobulin Reduces Tau Pathology and Preserves Neuroplastic Gene Expression in the 3xtg Mouse Model of Alzheimer’s Disease

Signal loss due to oligomerization in ELISA analysis of amyloid-beta can be recovered by a novel sample pre-treatment method